<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

1 min read

Increased COVID Headwinds Shut Down Procedures: Q220 Trauma Market Recap

By Doug Devens on 9/17/20 10:45 AM

Headwinds increased in Q2 as COVID-19 shut down elective procedures and stay-at-home orders impacted trauma volumes, but by the end of the quarter tailwinds picked up and it was smooth flying.

Q220 started out in a stall and continued to nosedive, as the Trauma segment experienced decreased admissions in April and May due to stay at home orders that caused a decrease in daily activities, including limited driving for most of the US. The US Trauma Market was down -14.2% YoY, with WW revenues declining -16.2%.

In June tailwinds picked up as stay at home orders began to lift and activities resumed, which boded well for the Trauma segment. Trauma procedures started to rebound in June, as most hospitals resumed surgeries depending upon PPE and OR time and resources. 

Among the many topics covered in the comprehensive Q220 Trauma Market Recap* are:

Continue Reading
2 min read

The Market Collapses: Q220 US Surgical Matrices Recap

By Doug Devens on 9/14/20 9:17 AM

The US Surgical Matrices Market collapsed in Q220, achieving sales of $227.3MM, off -39.4% YoY, as the effects of COVID-19 became evident with many delayed or canceled surgeries. The problems were evident everywhere, where Breast Matrices dropped -46.4 YoY to $69.6MM in Q220, while Hernia Matrices fell off -35.7% YoY to $157.7MM.

With COVID’s toll on delayed and canceled elective surgeries affecting all participants in the market, the US Surgical Matrices Market yielded -39.4% YoY, according to BioMedGPS’ SmartTRAK Financial DashboardAllergan* held on to its lead despite the effects of the pandemic, giving back -46.9%. Becton Dickinson* (BD) lost less than Allergan, declining -36.8%. However, Medtronic* announced that its hernia business was recovering faster than it expected.

Among the many topics covered in the comprehensive Q220 US Surgical Matrices Market Recap* are:

Continue Reading
2 min read

A Precipitous Drop: Q220 US Hemostats and Sealants Market Recap

By Doug Devens on 9/10/20 9:33 AM

The US market for Hemostats and Sealants dropped precipitously by -32.4% YoY in Q220, as the effects of COVD-19 became evident with many delayed or canceled surgeries.

With COVID’s toll on delayed and canceled elective surgeries affecting all participants in the market, the US Hemostats and Sealants market dropped -32.4% in Q220 according to SmartTRAK Financial Dashboard, a decrease that was presaged in Q120 earnings reports. Baxter* led the decline in Q220, down -42.1% YoY, with the Company’s sealants experiencing the worst YoY shrinkage. Cryolife* was close behind as its BioGlue* franchise saw cardiac surgeries postponed nationwide. In Q220, Ethicon* remained the market leader, followed by Baxter.

Among the many topics covered in the comprehensive Q220 US Hemostats and Sealants Market Recap* are:

Continue Reading
2 min read

Two Strikes then a Whole New Ballgame: Q220 Extremities Market Recap

By Lisa Mahan on 9/8/20 8:24 AM

Continue Reading
1 min read

Knees Take a Hit: Q220 Total Joints Market Recap

By Lisa Mahan on 9/3/20 9:30 AM

The full force of elective procedure shutdowns blasted away at the Total Joints Market in Q220, but Knees took the biggest hit as a higher percentage of knee replacements are considered elective.

As a result of COVID-19, elective procedure shutdowns in early Q220 blasted away at revenue results for the US Total Joints Market. When the dust settled, the US Market for Hips and Knees was down -41.9% according to SmartTRAK Financial Dashboard. US Knees experienced the biggest hit due to its exposure from a higher percentage of elective procedures compared to Hips. US Hips did not come through unscathed but suffered less damage.

Among the many topics covered in the comprehensive Q220 Total Joints Market Recap* are:

Continue Reading
4 min read

COVID-Era Consolidation in Spine

By Julianne Burns on 8/20/20 10:19 AM

Tracking the surge of Spine M&A activity during COVID-19.

The med device market downturn related to COVID-19 has led to a notable uptick in M&A activity across the board, with a number of acquisitions that will impact the Spine market.

Recent Deals
Perhaps the most notable deal has been Medtronic's* (MDT) agreement to acquire Medicrea, a manufacturer of custom spine implants, for about €7.00 per share, a premium of 22% over the closing price of shares on July 14. The acquisition is expected to close by the end of 2020.

Continue Reading
8 min read

SmartTRAK Trauma Market Updates: A COVID-19 Recovery on the Horizon?

By Thomas Wallick on 8/18/20 8:00 AM

Although COVID-19 has disrupted the medical device market, with many elective procedures being postponed, SmartTRAK anticipates the Trauma market to recover in 2021 and beyond. We anticipate that US Trauma fracture fixation procedures will be only slighted impacted by COVID-19, resulting in nearly flat YoY growth from 2019 to 2020 and believe that 2021 procedures will return to normal. This will result in 2021 procedural growth rates being inflated at ~10% and 2022 experiencing normal growth trends as volumes begin to stabilize. 

The following is just a small sampling of the Trauma market updates from around the world compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, financial data and competitor developments in the global Life Sciences industry.

Intramedullary Device w/ a Guided Growth System

A US Patent “Intramedullary device” was granted to Sydney Children’s Hospitals Network of New South Wales, AU, describing a device system & method for providing stabilization of a bone & configured to allow extension of the device w/ the growth of the bone. 10,736,674

Ilizarov Method for Nonunion of the Tibia

Union was achieved at mean length of 8.3 mos in all 102 pts w/ tibial nonunion treated w/ an Ilizarov ex fix w/ 95.1% maintaining union at least 2 yrs post treatment leading a study to conclude the Ilizarov method is an excellent long-term option. Arch Orthop Trauma Surg

Inverted or Non-Inverted Triangle Configuration for Femoral Neck Fxs

A non-inverted triangular configuration of 6.5mm screws used in the fixation of femoral neck fxs carries a higher risk of bony violation than an inverted triangle configuration concluded a study of 72 cases. J Clin Orthop Trauma

Continue Reading
10 min read

MedTech Innovation in the Time of COVID

By Thomas Wallick on 8/11/20 8:00 AM

Despite the unprecedented challenges of the ongoing pandemic, and the collateral economic hit taken due to the massive decline in elective procedures in Q220, MedTech companies continue to innovate and introduce new products to the global life sciences industry.

The following is just a small sampling of the new products updates from around the world compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, financial data and competitor developments in the global Life Sciences industry.

In Q220, Alphatec commenced upgrades of its cervical portfolio with 510(k) clearance of the Insignia Anterior Cervical Plate System and InVictus CT Spinal Fixation System, which expands InVictus across cervical, thoracic and lumbar procedures.

GMED has launched 6 new products in 2020 w/ strong uptake of HEDRON 3D printed IBD spacers as well as SABLE expandable MIS TLIF device. Globus is doubling its 3D manufacturing capacity which should come online in Q4. GMED Q220 Earnings Transcript on Seeking Alpha

Alpha launches for COHERE TLIF O and TLIF A are slated for 2020, expanding the Company’s proprietary porous PEEK platform. NUVA Q220 Earnings Transcript on Seeking Alpha

Topics: COVID-19
Continue Reading
8 min read

International MedTech News Updates: The Week in Review

By Thomas Wallick on 8/4/20 8:40 AM

The unprecedented challenges from the current resurgence of COVID-19 cases worldwide continues to concern the MedTech industry as it strives to develop ways to deal with a post-pandemic world. Despite the struggling global economy, demand for innovative medical devices and advanced technologies will continue to drive long term growth.
 
The following is just a small sampling of the updates from around the world compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.
 
June in Russia

In the pharmacies in Russia, commercial drug June sales increased by 0.1% in value vs May 2020. Compared to June 2019, sales increased by 2.1%. The increase in the first 6 mos in 2020 was 13.9% vs the same period in 2019.

Teleconsultation in France

During the lockdown in April, 27% of all consultations were teleconsultations in France. Of doctors carrying out teleconsultations, 50% were under 50 yrs old, though that age group represents only 37% of all GPs.

MedTech World in Germany

MedTech companies in Germany expect sales to decline an avg of 8% in 2020 due to the pandemic, including 12% in int’l business according to a survey. Almost 60% of companies expect a double-digit drop.

Continue Reading
8 min read

Recovery Predictions, Elective Surgery and Future Outbreaks: COVID-19 Updates

By Thomas Wallick on 7/20/20 1:40 PM

As the COVID-19 pandemic progresses and continues to affect everyday life around the world, the path that lies ahead for the MedTech industry and the search for effective therapeutics and vaccines remains hard to predict.

The following is a small sampling of the updates compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor  the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.

SVBLeerink Expects Q2 Recovery to Exceed Expectations 
Based on prelim Q220 MedTech Company results, SVB Leerink expects May/June COVID recovery to exceed expectations noting elective procedure shutdowns are regionalized and halts are not expected to be as bad or prolonged as in March/April. SVBLeerink Medical Supplies and Devices
 
Positive COVID-19 Vaccine Data Could Fuel Medtech Sectors

With 4 of the leading vaccine candidates expected to enter Phase 3 studies in July (Sinovac, Moderna, BioNTech/PFE, CanSino), Phase 2 data could be reported in summer/fall 2020. If +, WFS says it could be a catalyst for some medtech sectors in recovery of elective procedures.

Public Perception of Resuming Elective Surgery

A survey assessing public perceptions towards resuming elective surg found out of 722 people 61% were concerned w/ contracting COVID-19 during surg. Overall, 57% would have surgery at a hospital vs outpatient and 27% would undergo surg in the first mo of reopening. J Arthroplasty

Preparation for Future Outbreaks

The European Commission published a document about the preparedness of health systems in Europe for future COVID-19 outbreaks. Topics comprise testing, contact tracing, surveillance, accessibility of medical devices and capacity measures.

Continue Reading

    Recent Articles